Inactivating BAP1 mutations have been associated with inferior outcomes in rhabdoid meningioma and meningioma with rhabdoid features, and routine tumor testing for this mutation may aid prognostication in lower grade tumors with rhabdoid features. This evidence concerns the gene BAP1 and Rhabdoid Meningioma.